Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431961 | 0.90 | MCHR1 (0.44) | MCHR1ACHEMLNRHTR2CTHRA | |
| SCHEMBL5418562 | 0.90 | HRH3 (0.45) | MCHR1ACHEHTR2CTHRATHRB | |
| SCHEMBL5421012 | 0.89 | MCHR1 (0.43) | MCHR1ACHEHTR2C | |
| SCHEMBL5422848 | 0.89 | MCHR1 (0.43) | MCHR1ACHE | |
| SCHEMBL5422835 | 0.87 | MCHR1 (0.41) | MCHR1ACHEMLNRTHRATHRB | |
| SCHEMBL5428817 | 0.86 | MCHR1 (0.43) | MCHR1ACHEDRD2HTR2AHTR2C | |
| SCHEMBL5420452 | 0.86 | ACHE (0.52) | MCHR1ACHEHTR2CTHRATHRB | |
| SCHEMBL5418939 | 0.86 | MCHR1 (0.54) | MCHR1ACHEDRD2HTR2AHTR2C | |
| SCHEMBL5429436 | 0.85 | MCHR1 (0.43) | MCHR1ACHEDRD2HTR2AHTR2C | |
| SCHEMBL5415513 | 0.85 | MCHR1 (0.46) | MCHR1ACHEDRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20030158177-A1 | Treating or preventing obesity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158177-A1 | Treating or preventing obesity | MCHR1, MC1R, NPY1R | MCHR1 1/4885ACHE 4544/4885MLNR 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.